title: Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness.
abstract: Formal studies have not been performed to assess the cost-effectiveness of screening strategies for endocrine causes of hypertension. However, an understanding of the diagnostic accuracy of available screening tests and the clinical settings where disease identification will lead to improved health outcomes form the basis for a cost-effective strategy. Primary aldosteronism screening should be selective and restricted to settings where knowledge of the diagnosis has the greatest chance of improving health outcomes. Pheochromocytoma is rare; however, because it is a potentially fatal disease, screening strategies should err on the side of not missing the diagnosis, especially in high-risk clinical settings.
authors.affiliation: Division of Nephrology and Hypertension, College of Medicine, Mayo Clinic, West 19, Mayo Building, 200 First Street SW, Rochester, MN 55905, USA. schwartz.gary@mayo.edu
authors.forename: Gary L
authors.initials: GL
authors.lastname: Schwartz
mesh_terms: D000307:Adrenal Gland Diseases / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D000328:Adult; D002648:Child; D003362:Cost-Benefit Analysis; D006801:Humans; D006929:Hyperaldosteronism / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D006973:Hypertension / Q000453:epidemiology / Q000209:etiology*; D008403:Mass Screening / Q000191:economics* / Q000379:methods*; D010673:Pheochromocytoma / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D015995:Prevalence; D012680:Sensitivity and Specificity